Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the roles of lesser-known secreted phospholipase A2 isoforms in various biological processes, such as immune suppression, metabolic regulation, epidermal hyperplasia, and male reproduction, without reporting new clinical findings.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

This review discusses the isolation, structure, and bioactivity of lignans and neolignans from 2016 to mid-2018, reporting no new clinical results but highlighting their potential protective properties against diseases such as cancer and neurodegeneration.

This article contains the late-breaking abstracts from the 39th Annual Conference of the American Society for Laser Medicine and Surgery and does not present new research results.

This study found that Camellia oleifera seed shell polyphenols and 1,3,6-tri-O-galloylglucose improved androgenetic alopecia symptoms in mice by reducing DHT levels and activating specific hair growth pathways.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

This review discusses the roles of key epithelial-mesenchymal transition factors and potential therapeutic opportunities involving cancer metabolic pathways, reporting no new clinical results.

This study indicates that the EQ-5D-5L may not effectively capture the burden of alopecia areata on patients' health-related quality of life, and suggests that alternative measures might better assess treatment benefits related to hair regrowth.

This study observed a high prevalence of severe markers among pediatric alopecia areata patients, identifying AA subtotalis as more frequent, with nail changes and various hair markers suggesting progression to severe forms.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

This case report describes a 54-year-old woman who developed hypertrichosis around a leg ulcer while using PGE1 ointment, suggesting a potential side effect of the treatment.

This review discusses how dysregulated levels of eicosanoids, which are metabolites of phospholipids, may contribute to skin diseases like psoriasis and atopic dermatitis, suggesting the importance of targeted eicosanoid control in diagnosis and treatment.

This scoping review describes the current use of artificial intelligence in alopecia research, highlighting AI's evolution from diagnostic to prognostic applications in dermatology and identifying gaps in multimodal integration and fairness across demographics.

This study found that in Asian patients aged 12 and older with alopecia areata and significant hair loss, ritlecitinib showed clinical efficacy in improving hair regrowth and eyebrow and eyelash scores over 48 weeks, with an acceptable safety profile observed throughout.

This study found a positive association between clinically meaningful scalp hair regrowth and improvements in patient-reported outcomes, such as satisfaction and reduced psychosocial burden.

This study found that Annurca apple polyphenolic extracts reprogram hair follicle metabolism in mice, enhancing mitochondrial activity and keratin production while inhibiting some metabolic pathways.

This chapter reviews the pathogenesis, diagnosis challenges, associated comorbidities, and management of polycystic ovary syndrome in adolescents, but reports no new clinical findings.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

This study found that treatment with ritlecitinib improved hair regrowth in alopecia areata patients, with many achieving significant results after 24 weeks compared to placebo.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This article reviews the pharmacology of bimatoprost and prostamide F2α, highlighting bimatoprost's therapeutic applications in glaucoma, hair growth, and potential fat reduction, without reporting new experimental results.

This abstract reviews the evolution of hair restoration techniques, from 19th-century surgical scalp flaps to modern FUE and FUT methods, without providing new clinical findings.

This review discusses the roles of prostaglandins in the nervous system and their therapeutic potential for neurological diseases, noting their complex interactions with immune cells and signaling pathways.

This review suggests that annurca apple extract, rich in polyphenols, may be a promising alternative for treating baldness, though further research is needed to clearly assess its effectiveness compared to existing treatments.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

This review found that the DLQI is widely used as a benchmark in the development and validation of dermatology quality-of-life measures.

This study discusses the role of CD8+ T-cell and interferon γ signaling in vitiligo's pathogenesis and notes that JAK inhibitors, which are FDA-approved for other autoimmune diseases, may offer a potential treatment path by blocking this pathway.

In this study, oral Bhringaraj extract was found to significantly reduce hair shedding in adults over 24 weeks, according to comb test measurements and patient-reported improvements, with mild and self-resolving side effects observed.

This study found that the Alopecia Areata Patient Priority Outcomes questionnaire is a reliable and valid tool for measuring the severity and impact of hair loss in individuals with alopecia areata.